{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:10:06Z","timestamp":1748365806001,"version":"3.41.0"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T00:00:00Z","timestamp":1745107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>As a marker of minimal residual disease in B-cell acute lymphoblastic leukemia (B-ALL), CD58 has been reported in B-ALL at diagnosis and short-term follow-ups after standard chemotherapies. However, there are no data available in relapsed\/refractory (r\/r) patients who have received long-term and multiline therapies, especially chimeric antigen receptor (CAR) T cells; here, we focused on investigating CD58 status in these patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>CD58 expression on lymphoblasts was detected by multiparameter flow cytometry. CD58 status was evaluated in patients with r\/r B-ALL before CAR-T therapy, and the patients who failed or relapsed after CAR-T.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 274 pediatric and adult patients prior to exposure to CAR-T cells (22.3% of them underwent allogeneic hematopoietic cell transplantation, allo-HCT), 228 (83.2%) showed CD58 positivity. Furthermore, among 58 patients who were CD58 positive before CAR-T failed or relapsed after CAR-T (half also received CD22 CAR-T or allo-HCT as a consolidation treatment following CD19 CAR-T), the frequency of CD58 expression was 79.3% (46\/58) in all patients and 86.2% (25\/29) in patients exposed to CD19 CAR-T cells alone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>CD58 antigen was stably expressed in patients with r\/r B-ALL after multiline therapies, including allo-HCT and CAR-T, indicating that it could still be a leukemic marker in heavily treated patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqae166","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T13:42:29Z","timestamp":1745156549000},"page":"644-648","source":"Crossref","is-referenced-by-count":0,"title":["CD58 could be a leukemic marker in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia after multiline therapies"],"prefix":"10.1093","volume":"163","author":[{"given":"Xinjian","family":"Yu","sequence":"first","affiliation":[{"name":"Division of Flow Cytometry, Medical Laboratory, Beijing Gobroad Boren Hospital , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Flow Cytometry, Medical Laboratory, Beijing Gobroad Boren Hospital , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heyuan","family":"Feng","sequence":"additional","affiliation":[{"name":"Division of Flow Cytometry, Medical Laboratory, Beijing Gobroad Boren Hospital , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Flow Cytometry, Medical Laboratory, Beijing Gobroad Boren Hospital , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafeng","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Flow Cytometry, Medical Laboratory, Beijing Gobroad Boren Hospital , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9982-7099","authenticated-orcid":false,"given":"Shuangyou","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Gobroad Boren Hospital , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,20]]},"reference":[{"issue":"1","key":"2025052712483319600_CIT0001","doi-asserted-by":"publisher","first-page":"705260","DOI":"10.3389\/fimmu.2021.705260","article-title":"CD58 Immunobiology","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol."},{"issue":"7","key":"2025052712483319600_CIT0002","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood.v97.7.2115","article-title":"Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia","volume":"97","author":"Chen","year":"2001","journal-title":"Blood."},{"issue":"11","key":"2025052712483319600_CIT0003","first-page":"1245","article-title":"Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia","volume":"88","author":"Veltroni","year":"2003","journal-title":"Haematologica."},{"issue":"16","key":"2025052712483319600_CIT0004","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med."},{"issue":"5","key":"2025052712483319600_CIT0005","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med."},{"issue":"6","key":"2025052712483319600_CIT0006","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am J Hematol."},{"issue":"25","key":"2025052712483319600_CIT0007","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood."},{"issue":"1","key":"2025052712483319600_CIT0008","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1309\/x5vv6fkjq6mublpx","article-title":"CD58 expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia","volume":"123","author":"Lee","year":"2005","journal-title":"Am J Clin Pathol."},{"issue":"4","key":"2025052712483319600_CIT0009","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/cyto.b.22060","article-title":"Quick identification of target antigens by tissue flow cytometry for CAR-T therapy in B-cell malignancies","volume":"102","author":"Yu","year":"2022","journal-title":"Cytometry B Clin Cytom."},{"volume-title":"NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. Version 5","year":"2017","author":"National Comprehensive Cancer Network","key":"2025052712483319600_CIT0010"},{"issue":"1","key":"2025052712483319600_CIT0011","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cyto.b.22153","article-title":"Immunophenotypic portrait of leukemia-associated-phenotype markers in B acute lymphoblastic leukemia","volume":"106","author":"Boris","year":"2024","journal-title":"Cytometry B Clin Cytom."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/163\/5\/644\/62957584\/aqae166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/163\/5\/644\/62957584\/aqae166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:48:42Z","timestamp":1748364522000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/163\/5\/644\/8116539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,20]]},"references-count":11,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,4,20]]},"published-print":{"date-parts":[[2025,5,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqae166","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"type":"print","value":"0002-9173"},{"type":"electronic","value":"1943-7722"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,20]]}}}